Tigecycline is a glycylcycline antibacterial agent for intravenous infusion. Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. To date there has been no cross-resistance observed between Tigecycline and other antibacterials. Tigecycline is not affected by the two major Tetracycline-resistance mechanisms- ribosomal protection and efflux. Additionally, Tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target-site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerases).
Tigacil IV Infusion 50 mg
Community-acquired pneumonia: Initially, 100 mg as a single dose followed by 50 mg 12 hrly for 7-14 days. Infuse dose over 30-60 min.
Complicated intra-abdominal infections, Complicated skin and skin structure infections: 100 mg as a single dose, followed by 50 mg 12 hrly for 5-14 days. Infuse dose over 30-60 min.